Literature DB >> 17136319

Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.

Penny Clarke1, Kenneth L Tyler.   

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) shows promise as a chemotherapeutic agent. However, many human cancer cells are resistant to killing by TRAIL. We have previously demonstrated that reovirus infection increases the susceptibility of human lung (H157) and breast (ZR75-1) cancer cell lines to TRAIL-induced apoptosis. We now show that reovirus also increases the susceptibility of human ovarian cancer cell lines (OVCAR3, PA-1 and SKOV-3) to TRAIL-induced apoptosis. Reovirus-induced increases in susceptibility of OVCAR3 cells to TRAIL require virus uncoating and involve increased activation of caspases 3 and 8. Reovirus infection results in the down-regulation of cFLIP (cellular FLICE inhibitory protein) in OVCAR3 cells. Down-regulation of cFLIP following treatment of OVCAR3 cells with antisense cFLIP oligonucleotides or PI3 kinase inhibition also increases the susceptibility of OVCAR3 cells to TRAIL-induced apoptosis. Finally, over-expression of cFLIP blocks reovirus-induced sensitization of OVCAR3 cells to TRAIL-induced apoptosis. The combination of reovirus and TRAIL thus represents a promising new therapeutic approach for the treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17136319      PMCID: PMC2365758          DOI: 10.1007/s10495-006-0528-4

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  68 in total

1.  Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis.

Authors:  Alan D Brooks; Thomas J Sayers
Journal:  Cancer Immunol Immunother       Date:  2004-12-22       Impact factor: 6.968

2.  Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.

Authors:  Peter Horak; Dietmar Pils; Alexandra Kaider; Alexander Pinter; Katarzyna Elandt; Cornelia Sax; Christoph C Zielinski; Reinhard Horvat; Robert Zeillinger; Alexander Reinthaller; Michael Krainer
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

3.  Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.

Authors:  Sharmila Shankar; Thiyam R Singh; Tamer E Fandy; Thitidaj Luetrakul; Douglas D Ross; Rakesh K Srivastava
Journal:  Int J Mol Med       Date:  2005-12       Impact factor: 4.101

4.  In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.

Authors:  A El-Zawahry; P Lu; S J White; C Voelkel-Johnson
Journal:  Cancer Gene Ther       Date:  2006-03       Impact factor: 5.987

5.  15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins.

Authors:  Roberto Piva; Patrizia Gianferretti; Alessandra Ciucci; Riccardo Taulli; Giuseppe Belardo; M Gabriella Santoro
Journal:  Blood       Date:  2004-10-21       Impact factor: 22.113

6.  Molecular determinants of response to TRAIL in killing of normal and cancer cells.

Authors:  K Kim; M J Fisher; S Q Xu; W S el-Deiry
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

7.  Reovirus oncolysis in human head and neck squamous carcinoma cells.

Authors:  Yoichi Ikeda; Goshi Nishimura; Shunsuke Yanoma; Akira Kubota; Madoka Furukawa; Mamoru Tsukuda
Journal:  Auris Nasus Larynx       Date:  2004-12       Impact factor: 1.863

8.  The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.

Authors:  J E Strong; M C Coffey; D Tang; P Sabinin; P W Lee
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

9.  Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis.

Authors:  Simone Boehrer; Daniel Nowak; Elena Puccetti; Martin Ruthardt; Nicole Sattler; Bettina Trepohl; Bernd Schneider; Dieter Hoelzer; Paris S Mitrou; Kai Uwe Chow
Journal:  Leuk Res       Date:  2006-03-02       Impact factor: 3.156

10.  FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis.

Authors:  H Perlman; L J Pagliari; C Georganas; T Mano; K Walsh; R M Pope
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

View more
  11 in total

1.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

2.  Critical role for death-receptor mediated apoptotic signaling in viral myocarditis.

Authors:  Roberta L DeBiasi; Bridget A Robinson; J Smith Leser; R Dale Brown; Carlin S Long; Penny Clarke
Journal:  J Card Fail       Date:  2010-11       Impact factor: 5.712

3.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 4.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

5.  Daxx upregulation within the cytoplasm of reovirus-infected cells is mediated by interferon and contributes to apoptosis.

Authors:  Kalen R Dionne; Yonghua Zhuang; J Smith Leser; Kenneth L Tyler; Penny Clarke
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

Review 6.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23

Review 7.  Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer.

Authors:  Xiao-Yu Yan; Xian-Zhi Qu; Long Xu; Si-Hang Yu; Rui Tian; Xin-Ru Zhong; Lian-Kun Sun; Jing Su
Journal:  Cancer Cell Int       Date:  2020-04-16       Impact factor: 5.722

8.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

Review 9.  Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells.

Authors:  Jun Gong; Monica M Mita
Journal:  Front Oncol       Date:  2014-06-26       Impact factor: 6.244

Review 10.  Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.

Authors:  Alexander Malogolovkin; Nizami Gasanov; Alexander Egorov; Marianna Weener; Roman Ivanov; Alexander Karabelsky
Journal:  Viruses       Date:  2021-06-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.